Side-by-side · Research reference
EpitalonvsPT-141
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AHuman-MechanisticDraft8/37 cited
BFDA-ApprovedReviewed13/41 cited
Epitalon
Pineal bioregulator · Telomerase activator
SQ or IM · Abdomen · Daily for 10–20 days
PT-141
MC4R Agonist · FDA-Approved (HSDD)
SQ · Abdomen / thigh · ≥45 min before sex
01Mechanism of Action
Parameter
Epitalon
PT-141
Primary target
Telomerase activity (proposed); pineal melatonin axis modulationKhavinson 2003
Melanocortin-4 receptor (MC4R) in hypothalamusSimerly 2023VYLEESI (bremelanotide injecti 2019
Pathway
Activation of telomerase reverse transcriptase (hTERT) in somatic cells; pineal-axis modulation supports endogenous melatoninKhavinson 2003
MC4R agonism in paraventricular nucleus → autonomic + neuroendocrine sexual arousal pathwaysSimerly 2023
Downstream effect
Telomere elongation, improved sleep architecture, reported lifespan extension in aged miceKhavinson 2003
Increased sexual desire and arousal; central rather than peripheral mechanismClayton 2015
Feedback intact?
—
—
Origin
Synthetic 4-AA peptide derived from epithalamin (a natural pineal extract)Khavinson 2003
Cyclic 7-AA peptide derived from α-MSH (agonist Ac-Nle-Asp-His-D-Phe-Arg-Trp-Lys-OH cyclic)VYLEESI (bremelanotide injecti 2019
Antibody development
—
—
02Dosage Protocols
Parameter
Epitalon
PT-141
Standard dose
5–10 mg / day for 10–20 days, 1–2× per yearKhavinson 2003
Anecdotal community protocol. Russian clinical literature uses similar cycling.
1.75 mg SQVYLEESI (bremelanotide injecti 2019
Single dose ≥45 min before anticipated sexual activity. Max 1 dose / 24 hr.
Frequency
Once daily during a cycle
PRN, max 8 doses / month
Lower / starter dose
2.5 mg / day
1 mg (off-label)
Evidence basis
In-vitro telomerase + Russian clinical trialsKhavinson 2003
FDA-approved (HSDD pre-menopausal women)VYLEESI (bremelanotide injecti 2019Clayton 2015
Duration
10–20 day cycles, 1–2× per year
PRN; reassess if no benefit after 8 doses
Reconstitution
Bacteriostatic water
Pre-filled commercial pen (Vyleesi). Research vial: bacteriostatic water.
Timing
Pre-sleep preferred (pineal alignment)
≥45 min before sexual activity
04Side Effects & Safety
Parameter
Epitalon
PT-141
Injection site reaction
Mild irritation
Erythema, mild pain
Sleep architecture
Improved subjective sleep quality (anecdotal)
—
Cancer risk
Theoretical via telomerase activation in pre-malignant cells
—
Long-term safety
Limited Western RCT data
—
Pregnancy / OB
Avoid
Contraindicated
Antibody formation
Not reported
—
Flushing
—
Common, transient
Headache
—
Common
Hyperpigmentation (focal)
—
Rare focal skin darkening; reversible after discontinuationVYLEESI (bremelanotide injecti 2019
Hypertension (transient)
—
Mean ↑6 mmHg systolic peaking ~4 h post-dose; resolves within 12 hVYLEESI (bremelanotide injecti 2019
Cardiovascular disease
—
Use caution; transient BP rise
Absolute Contraindications
Epitalon
- ·Pregnancy / breastfeeding
- ·Active malignancy or pre-malignant state
PT-141
- ·Uncontrolled hypertension
- ·Known cardiovascular disease (caution)
- ·Pregnancy
Relative Contraindications
Epitalon
- ·Family history of cancer
PT-141
- ·Pre-existing hyperpigmentation disorders
- ·MC4R-pathway-dependent psychiatric conditions
05Administration Protocol
Parameter
Epitalon
PT-141
1. Reconstitution
Add 1–2 mL bacteriostatic water to 10 mg vial → 5–10 mg/mL.
Vyleesi: pre-filled auto-injector. Research vial: 2 mL bacteriostatic water per 10 mg → 5 mg/mL.
2. Injection site
SQ — abdomen preferred. Rotate sites.
SQ — abdomen or thigh.
3. Timing
Pre-sleep preferred to align with pineal axis.
≥45 min before sexual activity for peak effect. Effect persists ~6–8 h.
4. Storage
Lyophilised: room temp, light-protected. Reconstituted: refrigerate ≤30 days.
Vyleesi: room temp ≤30 °C. Research vial: refrigerate after reconstitution.
5. Needle
29–31G, 4–8 mm insulin syringe.
Auto-injector (Vyleesi) or 29–31G, 4–8 mm insulin syringe.